Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet + Cyclophosphamide + Metformin vs Myocet + Cyclophosphamide in first-line treatment of HER2-negative metastatic breast cancer
2009-014662-26Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of metformin in breast cancer (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: progression free survival. Started Jan 2010; status: active.
02
Drugs
metformin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-014662-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014662-26.